# Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

Source: https://onco.cc/trials/nct07864701/  
OnCo record `nct07864701` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JMBI-001 run by Chengdu Anticancer Bioscience, Ltd., now recruiting.

## Summary

Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers is a phase 1/2 interventional study registered as NCT07864701 by Chengdu Anticancer Bioscience, Ltd., with 150 participants planned, started 2026-10. Conditions recorded: Advance Solid Tumors and Lymphoma, Non-Hodgkin. Interventions recorded: JMBI-001 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07864701
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma
- Sponsor: Chengdu Anticancer Bioscience, Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07864701: https://clinicaltrials.gov/study/NCT07864701

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [JMBI-001](https://onco.cc/drugs/jmbi-001/)
- companies: [Anticancer Bioscience](https://onco.cc/companies/anticancer-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct07864701.json